Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mirati Therapeutics
(NQ:
MRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirati Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
Next >
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Via
Benzinga
EnerSys To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
December 20, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Analyst Expectations For Mirati Therapeutics's Future
December 20, 2023
Via
Benzinga
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
November 29, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
What 11 Analyst Ratings Have To Say About Mirati Therapeutics
November 07, 2023
Via
Benzinga
3 Resilient Stocks with Massive Potential to Boost Your Wealth
November 26, 2023
These three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life.
Via
InvestorPlace
These Three Biotech Stocks Are Trading At A Discount
November 23, 2023
Investors exposed to the biotech sector have seen mixed results this year.
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
November 17, 2023
Via
Benzinga
3 Biotech Stocks That Could Boom or Bust by 2025
November 16, 2023
Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday.
Via
InvestorPlace
MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
November 08, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
3 No-Brainer Stocks to Buy With $500 Right Now
November 08, 2023
A reasonably modest amount of money can go a long way when it's invested in time-tested businesses with sustained catalysts.
Via
The Motley Fool
Appian To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Tuesday
November 07, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
Via
Benzinga
Is MIRATI THERAPEUTICS INC Ready to Break Out of Its Range?
November 06, 2023
Investors are keeping a close eye on MIRATI THERAPEUTICS INC (NASDAQ:MRTX) as it boasts an impressive technical rating of 7 out of 10, signaling a possible breakout.
Via
Chartmill
7 Healthcare Stocks That Can Cure a Lackluster Portfolio
October 19, 2023
Take a position in these companies' stocks to achieve long-term gains and give a jolt to your investment portfolio.
Via
InvestorPlace
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings
October 19, 2023
Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or...
Via
Benzinga
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
October 17, 2023
Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to...
Via
PressReach
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer Natural Resources (NYSE - PXD), Summit Materials (NYSE
October 16, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade
October 11, 2023
The company has growing pipeline optionality, according to the upgrade report.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
October 10, 2023
Via
Benzinga
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
October 10, 2023
Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...
Via
PressReach
MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
October 09, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
October 09, 2023
Via
Benzinga
Why Shares of Tango Therapeutics Are Dropping Monday
October 09, 2023
Another company's buyout helped drive up the price last week. This week, investors started out by selling the stock.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 9, 2023
October 09, 2023
Via
Benzinga
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 09, 2023
Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near...
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mirati Therapeutics, Inc.® (Nasdaq - MRTX), LiveVox Holdings, Inc. (Nasdaq - LVOX), SP® Plus Corporation (Nasdaq - SP), Summit Materials (NYSE - SUM)
October 09, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid
October 09, 2023
Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion.
Via
Investor's Business Daily
Bristol Myers Squibb Strengthens Oncology Portfolio With Mirati Therapeutics' $5B Deal
October 09, 2023
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire Mirati Therapeutics Inc (NASDAQ: MRTX) for $58.00 per share in cash, for a total
Via
Benzinga
S&P 500, Nasdaq Set For Bleak Start To Week As Middle East Tensions Dampen Risk-On Mood: Earnings, Inflation Data In Focus
October 09, 2023
Trading in stock futures suggests a lower open on Monday as traders digest the ramification of the conflict in the Middle East.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Tesla, Mirati Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
October 09, 2023
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit